MedTrace Logo

Molecular Features and Pathways in Predicting Drug Resistance in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Enzalutamide

NCT02228265 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 41

Last updated 2020-09-28

No results posted yet for this study

Summary

This research trial studies molecular features and pathways in predicting drug resistance in patients with castration-resistant prostate cancer that has spread to other parts of the body and who are receiving enzalutamide. Studying samples of blood and tissue in the laboratory from patients receiving enzalutamide may help doctors learn more about molecular features and pathways that may cause prostate cancer to be resistant to the drug.

Conditions

  • Castration Levels of Testosterone
  • Castration-Resistant Prostate Carcinoma
  • Prostate Adenocarcinoma
  • PSA Progression
  • Recurrent Prostate Carcinoma
  • Stage IV Prostate Cancer

Interventions

OTHER

Cytology Specimen Collection Procedure

Undergo blood and tissue collection

DRUG

Enzalutamide

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

Sponsors & Collaborators

  • United States Department of Defense

    collaborator FED

  • Oregon Health and Science University

    collaborator OTHER

  • OHSU Knight Cancer Institute

    lead OTHER

Principal Investigators

  • Joshi Alumkal · OHSU Knight Cancer Institute

Eligibility

Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-03-12
Primary Completion
2019-10-01
Completion
2020-02-27

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02228265 on ClinicalTrials.gov